---
title: "From Idea to Impact: What EsoBiotec’s Billion-Dollar Exit Says About Belgium’s Biotech Ecosystem"
description: Discover how EsoBiotec’s billion-dollar exit highlights Belgium’s thriving biotech ecosystem and the value of the Advanced Master in Biotech & MedTech.
---

[Blog | Solvay Lifelong Learning ](https://exed.solvay.edu/en/blog)

# [From Idea to Impact: What EsoBiotec’s Billion-Dollar Exit Says About Belgium’s Biotech Ecosystem](https://exed.solvay.edu/en/blog/esobiotecs-billion-dollar-exit-says-about-belgiums-biotech)

 Written by [Marianna Rousaki](https://exed.solvay.edu/en/blog/author/marianna-rousaki) | 4/8/25 11:30 AM

*This article follows the *[*recent feature in*** L’Echo** *on EsoBiotec*](https://www.lecho.be/entreprises/yaka/esobiotec-l-histoire-wallonne-d-une-idee-a-un-milliard-de-dollars/10598666.html)*, a Walloon biotech start-up whose acquisition by AstraZeneca marks a new milestone for Belgium’s life sciences sector. We reflect on what this success story reveals about the country’s growing biotech ecosystem — and how it connects to the learning experience offered by the Advanced Master in Biotech and Medtech Ventures (AMBT).*

In March 2025, **Walloon biotech start-up *****EsoBiotec***** was acquired by AstraZeneca for up to $1 billion** — **a milestone for the Belgian life sciences sector **and a reflection of the strength and maturity of its innovation ecosystem.

Founded in 2020, EsoBiotec developed a new approach to cell therapy, making it faster, more scalable, and more accessible. It’s the kind of breakthrough that reflects a broader trend: Belgium is increasingly seen as a hub for biotech entrepreneurship and venture creation.

EsoBiotec’s story also reflects the kind of ecosystem our participants are immersed in during the **Advanced Master in Biotech and Medtech Ventures**. One of the company’s early backers, **InvestSudTech**, is both a shareholder in EsoBiotec and a sponsor of the AMBT. Our Academic Director, **Marc Dechamps**, serves as President of the Board at InvestSudTech, bringing direct industry insight into the classroom.

These connections highlight** the value of embedding learning within real-world entrepreneurial contexts**. Through the AMBT, participants not only gain business and scientific expertise - they also tap into the networks and perspectives that are shaping the next generation of biotech ventures.

EsoBiotec’s growth was also marked **by a strong network of Belgian public and private support**. The company benefited from early investments from regional actors like Sambrinvest and InvestSud Tech, and received multiple rounds of funding, including support from Walloon public authorities. 

 

> **This illustrates the robust financing landscape that is accessible to start-ups operating in life sciences within Belgium, especially those building on deep scientific expertise.**

 

The deal with AstraZeneca also signals how Belgian biotech companies can play a role in **addressing global healthcare challenges**. EsoBiotec’s platform technology for cell therapy responds to the growing demand for scalable, cost-effective treatment options, and the acquisition places this** Walloon innovation in a global spotlight**. For AMBT participants, it’s a reminder that science, strategy, and the right support can align to create a meaningful impact far beyond the lab.

 

* *

- Are you interested in joining our latest cohort? See all the information about the [Advanced Master in Biotech & MedTech Ventures on our programme page! ](https://exed.solvay.edu/11-program/1050-advanced-master-in-biotech-and-medtech-ventures?hsLang=en)
- [Read the original article in L’Echo](https://www.lecho.be/entreprises/yaka/esobiotec-l-histoire-wallonne-d-une-idee-a-un-milliard-de-dollars/10598666.html)

[View full post](https://exed.solvay.edu/en/blog/esobiotecs-billion-dollar-exit-says-about-belgiums-biotech)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Marianna Rousaki"
  },
  "dateModified" : "2025-04-08T11:31:00.407Z",
  "datePublished" : "2025-04-08T11:30:22Z",
  "headline" : "From Idea to Impact: What EsoBiotec’s Billion-Dollar Exit Says About Belgium’s Biotech Ecosystem",
  "image" : {
    "@type" : "ImageObject",
    "height" : 600,
    "url" : "https://exed.solvay.edu/hubfs/What%20EsoBiotec%E2%80%99s%20Billion-Dollar%20Exit%20Says%20About%20Belgium%E2%80%99s%20Biotech%20Ecosystem.png",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://exed.solvay.edu/en/blog/esobiotecs-billion-dollar-exit-says-about-belgiums-biotech",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60.0,
      "url" : "https://5255402.fs1.hubspotusercontent-na1.net/hubfs/5255402/Logo%20SLL%20x%20ULB.png",
      "width" : 450.24
    },
    "name" : "Blog"
  }
}
```